CN112292386B - 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物 - Google Patents

作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物 Download PDF

Info

Publication number
CN112292386B
CN112292386B CN201980039715.9A CN201980039715A CN112292386B CN 112292386 B CN112292386 B CN 112292386B CN 201980039715 A CN201980039715 A CN 201980039715A CN 112292386 B CN112292386 B CN 112292386B
Authority
CN
China
Prior art keywords
pyran
triazol
mmol
tetrahydro
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980039715.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN112292386A (zh
Inventor
R·A·哈茨
徐力
D·S·尹
A·雷盖罗-伦
P·R·雅拉加姆
M·潘达
S·K·奈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN112292386A publication Critical patent/CN112292386A/zh
Application granted granted Critical
Publication of CN112292386B publication Critical patent/CN112292386B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201980039715.9A 2018-06-15 2019-06-13 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物 Active CN112292386B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685395P 2018-06-15 2018-06-15
US62/685,395 2018-06-15
US201962831867P 2019-04-10 2019-04-10
US62/831,867 2019-04-10
PCT/US2019/036877 WO2019241461A1 (en) 2018-06-15 2019-06-13 Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors

Publications (2)

Publication Number Publication Date
CN112292386A CN112292386A (zh) 2021-01-29
CN112292386B true CN112292386B (zh) 2024-06-11

Family

ID=67297250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980039715.9A Active CN112292386B (zh) 2018-06-15 2019-06-13 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物

Country Status (7)

Country Link
US (1) US11970511B2 (https=)
EP (1) EP3807290B1 (https=)
JP (1) JP7190513B2 (https=)
KR (1) KR102802503B1 (https=)
CN (1) CN112292386B (https=)
ES (1) ES2912499T3 (https=)
WO (1) WO2019241461A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113366007A (zh) * 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
JP2022508719A (ja) * 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤のプロドラッグ
KR20230006547A (ko) * 2020-05-05 2023-01-10 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
EP4157833A1 (en) 2020-05-28 2023-04-05 Bristol-Myers Squibb Company Galectin-3 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113568A1 (en) * 2004-05-21 2005-12-01 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
CN102439021A (zh) * 2009-04-28 2012-05-02 南方佛斯卡专利公司 半乳凝素的新型半乳糖苷抑制剂
CN104755088A (zh) * 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
CN104955471A (zh) * 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
CN106536537A (zh) * 2014-07-09 2017-03-22 卡雷多生物技术公司 半乳凝素的新型杂合半乳糖苷抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
US20140243302A1 (en) 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections
US9021050B2 (en) 2012-08-31 2015-04-28 Yume, Inc. Network service system and method with off-heap caching
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP6904906B2 (ja) 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
ES2921500T3 (es) 2015-11-09 2022-08-26 Galecto Biotech Ab 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas
JP6844991B2 (ja) 2015-11-10 2021-03-17 サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． ジッパーを有する伸縮性衣類の製法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113568A1 (en) * 2004-05-21 2005-12-01 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
CN102439021A (zh) * 2009-04-28 2012-05-02 南方佛斯卡专利公司 半乳凝素的新型半乳糖苷抑制剂
CN104755088A (zh) * 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
CN104955471A (zh) * 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
CN106536537A (zh) * 2014-07-09 2017-03-22 卡雷多生物技术公司 半乳凝素的新型杂合半乳糖苷抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors;Li Xu, et al.;《J. Med. Chem.》;第64卷;第6634-6655页 *
孟繁浩 李柱来.《药物化学》.中国医药科技出版社,2016,(第2016年1月第1版版),第385-387页. *

Also Published As

Publication number Publication date
JP7190513B2 (ja) 2022-12-15
KR20210021015A (ko) 2021-02-24
EP3807290B1 (en) 2022-03-30
WO2019241461A1 (en) 2019-12-19
KR102802503B1 (ko) 2025-04-29
EP3807290A1 (en) 2021-04-21
CN112292386A (zh) 2021-01-29
US20210323991A1 (en) 2021-10-21
JP2021527102A (ja) 2021-10-11
US11970511B2 (en) 2024-04-30
ES2912499T3 (es) 2022-05-26

Similar Documents

Publication Publication Date Title
US11072626B2 (en) Small molecule inhibitors of Galectin-3
JP7514025B2 (ja) Ｊａｋ阻害剤化合物及びその使用
EP4691554A2 (en) Glp-1r modulating compounds
CN112292386B (zh) 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN112574199B (zh) Kras-G12C抑制剂杂环化合物
CN107148423B (zh) 硫代核苷衍生物或其盐及医药组合物
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
WO2019067702A1 (en) INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
HK1218256A1 (zh) 使用mek抑制劑的方法
JP2025519584A (ja) Ｋｒａｓ阻害剤としてのピリド［４，３－ｄ］ピリミジン誘導体
AU2019211382A1 (en) Aminopyrrolotriazines as kinase inhibitors
KR20180094514A (ko) 브루톤 티로신 키나제 억제제 및 이의 사용 방법
ES2984075T3 (es) Inhibidores de moléculas pequeñas de galectina-3
WO2023006013A1 (zh) 新型parp7抑制剂及其应用
WO2022066917A1 (en) 3-(6-aminopyridin-3-yl)benzamide derivatives as ripk2 inhibitors
CN115551855A (zh) 半乳凝素-3的小分子抑制剂
US12275718B2 (en) Small molecule inhibitors of galectin-3
HK1235794A1 (en) Thionucleoside derivative or salt thereof, and pharmaceutical composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant